Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric ...

The FDA has granted Breakthrough Therapy Designation to daridorexant for treating pediatric insomnia disorder, recognizing significant unmet medical need and positive Phase 2 clinical results. The designation facilitates closer FDA guidance to expedite daridorexant's development and potential approval for patients aged 10 to under 18.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it.